SteelPeak Wealth LLC Buys 6,810 Shares of Johnson & Johnson $JNJ

SteelPeak Wealth LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,071 shares of the company’s stock after purchasing an additional 6,810 shares during the quarter. SteelPeak Wealth LLC’s holdings in Johnson & Johnson were worth $17,398,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Analyst IMS Investment Management Services Ltd. lifted its position in Johnson & Johnson by 42.3% during the fourth quarter. Analyst IMS Investment Management Services Ltd. now owns 9,271 shares of the company’s stock valued at $1,918,000 after purchasing an additional 2,756 shares during the last quarter. 1900 Wealth Management LLC lifted its position in Johnson & Johnson by 45.6% during the fourth quarter. 1900 Wealth Management LLC now owns 8,219 shares of the company’s stock valued at $1,701,000 after purchasing an additional 2,574 shares during the last quarter. Aspiriant LLC lifted its holdings in shares of Johnson & Johnson by 3.0% in the 4th quarter. Aspiriant LLC now owns 19,866 shares of the company’s stock worth $4,111,000 after acquiring an additional 570 shares during the last quarter. Investment Planning Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $251,000. Finally, Cooksen Wealth LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $255,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 0.9%

Shares of NYSE JNJ opened at $240.87 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $251.71. The firm’s fifty day moving average is $240.25 and its 200 day moving average is $213.73. The company has a market cap of $580.15 billion, a price-to-earnings ratio of 21.80, a PEG ratio of 2.41 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion for the quarter. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on JNJ shares. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Thursday, March 5th. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Freedom Capital lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Morgan Stanley set a $253.00 price objective on shares of Johnson & Johnson in a report on Wednesday, March 18th. Finally, Stifel Nicolaus boosted their price objective on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $236.91.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.